ArticlePregnancy (Hoboken, N.J.)2026
A model to predict red blood cell transfusion during/after cesarean delivery.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Background: Cesarean delivery is a major risk factor for postpartum hemorrhage. A priority for postpartum hemorrhage safety bundles is the assessment of hemorrhage and transfusion risk following cesarean delivery and the identification of patients at increased risk for postpartum hemorrhage requiring red blood cell transfusion. A prediction model based on antenatal and intrapartum risk factors could be used in a standardized manner among all patients when considering crossmatch or other preparatory measures prior to cesarean delivery. Objective: To develop a multivariable prediction model for red blood cell transfusion associated with cesarean delivery using a prospective contemporary cohort. Methods: Secondary analysis of a multicenter trial of tranexamic acid (TXA) versus placebo for the prevention of red blood cell transfusion after cesarean delivery was performed. The primary outcome for this analysis was transfusion of packed red blood cells by hospital discharge or 7 days postpartum, whichever came first. Maternal characteristics and risk factors related to labor were compared between patients who received a transfusion and those who did not. Any of the characteristics that differed with a Results: A total of 418 of 10,961 patients (3.8%) received a red blood cell transfusion. Factors associated with transfusion and retained in the final model included gestational age at delivery <34 weeks or ≥41 weeks, chorioamnionitis, aspirin use in the week before delivery, preoperative hemoglobin level, preoperative platelet count <100,000, oxytocin duration, and cesarean delivery during the second stage of labor. The final multivariable model had excellent discrimination with an area under the curve (AUC) of 0.79 (95% confidence interval [CI], 0.76, 0.81). Using the same set of seven factors identified in the prediction model for transfusion, the AUC was 0.62 (95% CI, 0.60, 0.65) for differentiating patients who did and did not require surgical/radiological interventions in response to bleeding. Conclusion: We identified several factors associated with risk of red blood cell transfusion during/after cesarean delivery and a model with excellent predictive ability. Risk factors in this model, including lower preoperative hemoglobin level, aspirin use <7 days before delivery, and delivery during the second stage of labor, may be used to risk-stratify patients for preparation for transfusion to reduce postoperative complications that result from bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.